Table 1.
Variables | Placebo (group I, n=30) | NAC (group II, n=30) | P |
---|---|---|---|
Age, years | 70.50 (68.00–73.25) | 71.50 (69.00–73.50) | 0.212 |
Male, n, % | 73 | 60 | 0.281 |
BMI, kg/m2 | 28.27 (26.75–30.40) | 25.03 (22.84–28.20) | 0.015 |
LVEF, % | 56.50 | 60.00 | 0.424 |
DM, n, % | 47 | 50 | 0.800 |
HT, n, % | 57 | 43 | 0.310 |
PAD, n, % | 13 | 10 | 0.694 |
Smoking, n, % | 53 | 37 | 0.201 |
ACE Inh., n, % | 23 | 27 | 0.770 |
Duration of | |||
surgery, min | 240 (235–270) | 220 (210–250) | 0.434 |
CPB time, min | 99.33±22.50 | 91.47±22.06 | 0.362 |
Cross-clamp | |||
time, min | 54.00 (43.25–60.00) | 49.00 (39.25–62.00) | 0.626 |
Bleeding, mLa | 545 (380–713) | 565 (438–700) | 0.506 |
Red blood cells, | |||
Unitsb | 1.70±0.84 | 1.30±1.01 | 0.073 |
Urine output, mL | |||
PO day 1 | 2913±471 | 2982±534 | 0.599 |
PO day 2 | 2816±353 | 2674±436 | 0.170 |
Volume, mLc | 3330 (3088–3515) | 3100 (2900–3500) | 0.346 |
Bradycardiad, n, % | 10.00 | 6.67 | 0.647 |
Hypotensiond, n, % | 20 | 20 | 1.000 |
ICU stay, days | 1.57±0.50 | 1.63±0.61 | 0.648 |
Inotropic drug, n, % | 27 | 20 | 0.549 |
IABP, n, % | 6.67 | 3.33 | 0.561 |
Hospital stay, days | 5.93±1.17 | 6.20±1.16 | 0.379 |
Preoperative | |||
creatinine, mg/dL | 0.98±0.19 | 0.93±0.24 | 0.402 |
NGAL, ng/mL | 64.13±20.78 | 55.24±24.69 | 0.137 |
ACE Inh. - angiotensin-converting enzyme inhibitors; BMI - body mass index; CPB - cardiopulmonary bypass; DM - diabetes mellitus; HT - hypertension; IABP - intra-aortic balloon pump; ICU - intensive care unit; LVEF - left ventricular ejection fraction; NAC - N-acetyl cysteine; NGAL - neutrophil gelatinase-associated lipocalin; PAD - peripheral arterial disease; PO - postoperative;
total bleeding during the first 24 h postoperatively;
total units of packed red blood cell transfusion during intensive care unit follow-up;
total amount of volume received during the first 24 h postoperatively;
an episode longer than 10 min
Student’s t-test, Mann–Whitney U test, and chi-square test were used for the comparison of groups